

1/7/1

DIALOG(R)File 351:DERWENT WPI (c)1998 Derwent Info Ltd. All rts. reserv.
011594779 ***Image available** WPI Acc No: 98-011907/199802

Lipid-lowering drug and edible composition - contain iso-flavone derivative and are used for prophylaxis and treatment of hyperlipaemia, arteriosclerosis, etc.

Patent Assignee: FUJIKO KK (FUJI-N)

Number of Countries: 001 Number of Patents: 001

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
JP 9255570	A	19970930	JP 9664368	A	19960321	A61K-031/35	199802 B

Priority Applications (No Type Date): JP 9664368 A 19960321

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
JP 9255570	A		6			

Abstract (Basic): JP 9255570 A

A lipid-lowering drug comprises an isoflavone derivative of formula (I), where R1 = H or OH, and R2 = OH, O-glucoside, O-(6"-O-succinyl)glucoside, O-(6"-O-malonyl)glucoside or O-(6"-O-acetyl)glucoside. Also claimed is an edible composition containing (I).

(I) is daidzein, daidzin, 6"-O-succinyl daidzin, 6"-O-malonyl daidzin or 6"-O-acetyl daidzin. In an example, Sprague-Dawley female rats (11-week-old, n = 5) were subjected to ovariectomy. After 7 days, the rats were given daidzin (suspended in 1 % aqueous HPC) p.o. for 4 weeks and then fasted overnight. The serum levels of neutral fat, total cholesterol, HDL-cholesterol and LDL-cholesterol were measured. Daidzin reduced serum cholesterol levels dose-dependently in the range of 25-75 mg/kg/day.

USE - The drug and edible composition are useful for the prophylaxis and treatment of e.g. hyperlipaemia, arteriosclerosis, ischaemic cardiopathy and cerebrovascular disease. Daily dose of (I) is 0.1-4 (preferably 0.2-1) mg/kg.

ADVANTAGE - (I) is highly safe and reduces blood lipid levels, especially serum cholesterol levels.

Dwg. 0/0

Derwent Class: B02; D13; E13

International Patent Class (Main): A61K-031/35

International Patent Class (Additional): A23L-001/06; A23L-001/30;
A23L-002/52; A61K-031/70; C07D-311/36; C07H-017/07